Published 02-15-22
Issued by Novartis
At Novartis, we work to build trust with society and deliver long-term value to our stakeholders by embedding environmental, social and governance (ESG) topics into the core of our business strategy and operations. In February, we released our first Novartis in Society Integrated Report 2021, a new approach to reporting that describes how we create value for our stakeholders through our purpose to reimagine medicine to improve and extend people’s lives. For example, in 2021, our medicines reached 766 million patients in 2021, with 56.2 million of those reached through our various access-to-medicine approaches. The report is intended for all Novartis stakeholders, while meeting the specific needs of investors and ESG professionals through comprehensive and downloadable data on our performance.
At Novartis, we work to build trust with society and deliver long-term value to our stakeholders by embedding environmental, social and governance (ESG) topics into the core of our business strategy and operations.
In February, we released our first Novartis in Society Integrated Report 2021, a new approach to reporting that describes how we create value for our stakeholders through our purpose to reimagine medicine to improve and extend people’s lives. The report is intended for all Novartis stakeholders, while meeting the specific needs of investors and ESG professionals through comprehensive and downloadable data on our performance.
The Novartis in Society Integrated Report 2021 contains three main sections:
2021 HIGHLIGHTS
Commenting on the company’s 2021 performance, Novartis Chief Executive Officer Vas Narasimhan said: “Our impact on the world remains extraordinary. As we reimagine medicine at Novartis, our unwavering focus on our strategy and purpose enabled us to continue creating value for patients, healthcare professionals, healthcare systems, employees, shareholders and society.”
The Novartis in Society Integrated Report is prepared in accordance with leading frameworks and guidelines for corporate reporting, including the GRI Standards Core Option, SASB Standards, Integrated Reporting Framework, and Task Force on Climate-related Financial Disclosures (TCFD).
Access and download the full report at: reporting.novartis.com
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
This communication contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. This communication also contains non-IFRS measures. For more information and an explanation of non-IFRS measures please see the Novartis Fourth Quarter and Full Year 2021 Condensed Financial Report.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.